Clopidogrel versus aspirin for the secondary prevention of ischemic stroke and mortality in patients with cardiovascular disease: pharmacoeconomic aspect
DOI:
https://doi.org/10.24959/cphj.14.1290Keywords:
pharmacoeconomic analysis, clopidogrel, acetylsalicylic acid, secondary prevention, strokeAbstract
Aspirin, dipyridamole and clopidogrel are three widely used antithrombotic drugs for the purpose of the secondary prevention of stroke. Based on the results of many clinical studies it has been shown that aspirin and clopidogrel are effective, but both have potentially serious side effects, however, clopidogrel is more expensive than aspirin. The article presents the results of the evaluation of cost-effectiveness of using antiplatelet agents of clopidogrel compared to aspirin in patients with atherosclerosis with ischemic stroke (IS), myocardial infarction (MI) and peripheral artery disease for prevention of acute ischemic stroke and cardiovascular mortality according to the results of CAPRIE randomized clinical research. For pharmacoeconomic analysis such methods as mathematical modeling and decision tree analysis «cost – effectiveness» have been used. The results of CAPRIE randomized clinical trial have shown that the long-term use of clopidogrel in patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of IS, MI, or cardiovascular death. The common safety profile of clopidogrel is the same as for aspirin. The results of pharmacoeconomic analysis indicate that the use of clopidogrel as an antiplatelet agent in patients with cardiovascular disease for prevention of stroke compared to acetylsalicylic acid is more expensive for the payer, but provides additional effectiveness – two surviving lives when treating 1 000 patients.
References
Адонкіна В.Ю., Міщенко О.Я. // Укр. журн. клін. та лабораторної медицини. – 2012. – Т. 7, №3. – С. 195-199.
Яковлева Л.В., Бездетко Н.В., Герасимова О.А. и др. Фармакоэкономика: Учеб. пособ. для студ. вузов. – Х.: НФаУ, 2007. – 176 с.
Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – Р. 71-86.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. – 1996. – Vol. 348, №9038. – P. 1329-1339.
European Stroke Organization. Guidelines for Management of Ischaemic Stroke, 2008.
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008 The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee // Cerebrovasc. Dis. – 2008. – Vol. 25. – P. 457-507.
Rudd A.D., Hofman A., Irwin P. et al. // Stroke. – 2005. – Vol. 36. – Р. 103-106.
Sarti C., Rastenyte D., Cepaitis Z. et al. // Sroke. – 2000. – Vol. 31, №7. – Р. 1588-1601.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
